Trial · NCT01870921

Brilinta DaYu Study

NCT01870921, Phase 4, Completed, AstraZeneca; results first posted 2016-11-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Brilinta DaYu Study. Trials, record NCT01870921. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01870921

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Brilinta DaYu Study
NCT number: NCT01870921
Status: Completed
Phases: Phase 4
Enrollment: 2,004 participants, actual
Lead sponsor: AstraZeneca
Conditions: Acute Coronary Syndrome
Interventions: Ticagrelor
First posted: 2013-06-06
Last updated: 2018-04-03
Results first posted: 2016-11-09

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Bleeding Events	12 months	PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal
Primary	Serious Adverse Events Other Than Bleeding	12 months	SAEs except the blending events which have aleady been reported as SAEs.
Secondary	Major CV Events	12 months	Combination of CV death, MI, and stroke

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Bleeding Events	12 months	Participants	NUMBER
PRIMARY	Serious Adverse Events Other Than Bleeding	12 months	Participants	NUMBER
SECONDARY	Major CV Events	12 months	Participants	NUMBER

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Bleeding Events	Ticargrelor	Fatal/life threatening	17	Participants
Bleeding Events	Ticargrelor	Major	27	Participants
Bleeding Events	Ticargrelor	Major + minor	93	Participants
Bleeding Events	Ticargrelor	Major + minor + minimal	426	Participants
Serious Adverse Events Other Than Bleeding	Ticargrelor		116	Participants
Major CV Events	Ticargrelor		85	Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ticargrelor	2,004
Overall Study	COMPLETED	Ticargrelor	1,914
Overall Study	NOT COMPLETED	Ticargrelor	90

Source ClinicalTrials.gov

Adverse events111

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Ecchymosis	Skin and subcutaneous tissue disorders	Ticargrelor	113	2,001	130
other	Hyperuricaemia	Metabolism and nutrition disorders	Ticargrelor	130	2,001	132
serious	Upper Gastrointestinal Haemorrhage	Gastrointestinal disorders	Ticargrelor	16	2,001	16
serious	Gastrointestinal Haemorrhage	Gastrointestinal disorders	Ticargrelor	12	2,001	12
serious	Gastritis	Gastrointestinal disorders	Ticargrelor	4	2,001	5
serious	Duodenal Ulcer Haemorrhage	Gastrointestinal disorders	Ticargrelor	3	2,001	3
serious	Gastric Ulcer Haemorrhage	Gastrointestinal disorders	Ticargrelor	2	2,001	2
serious	Faeces Discoloured	Gastrointestinal disorders	Ticargrelor	1	2,001	1
serious	Gastritis Erosive	Gastrointestinal disorders	Ticargrelor	1	2,001	1
serious	Gingival Bleeding	Gastrointestinal disorders	Ticargrelor	1	2,001	1

1 to 10 of 111Source ClinicalTrials.gov

See all 111 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ticargrelor
Total, other adverse events	Ticargrelor	230	2,001
Total, serious adverse events	Ticargrelor	161	2,001

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
29488142	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01870921

GET https://conductscience.org/api/trials/v1/NCT01870921/events?page=2

API reference For AI assistants